Galectin Therapeutics
Presencia
Galectin Therapeutics es una empresa que cotiza bajo el símbolo de cotización GALT (US).
Ejecutivos
Ver el organigrama con sus 20 ejecutivos principales
Biografías más buscadas en Galectin Therapeutics
- Joel Lewis, President, Chief Executive Officer and Director
- Kary Eldred, Director
- Richard Uihlein, Chairman of the Board
Recientes movimientos de ejecutivos en Galectin Therapeutics
- Khurram Jamil, se ha incorporado a la empresa como Vice President, Clinical Development (noticia publicada el 13 de marzo de 2024).
- Benjamin Carson, se ha incorporado a la empresa como Director (noticia publicada el 12 de octubre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Galectin Therapeutics.
Biotecnología
Galectin Therapeutics tiene 2.273 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
- Nurix Therapeutics acaba de anunciar una recaudación de fondos de 175 millones de dólares. (publicado el 13 de abril de 2024).
- Nuvation Bio has announced the acquisition of AnHeart (publicado el 12 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Galectin Therapeutics
- Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 | Galectin Therapeutics Inc.
- Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress | Galectin Therapeutics Inc.
- Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer | Galectin Therapeutics Inc.
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- View more press releases Close
Redes sociales sobre Galectin Therapeutics
- Galectin Therapeutics en Wikipedia, Google News y Yahoo Finance
- Galectin Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Gilbert Amelio 
Llame a Galectin Therapeutics al +1 678...
